CN1079954A - 喷雾冷冻的萘丁酮和其生产方法 - Google Patents
喷雾冷冻的萘丁酮和其生产方法 Download PDFInfo
- Publication number
- CN1079954A CN1079954A CN93100940A CN93100940A CN1079954A CN 1079954 A CN1079954 A CN 1079954A CN 93100940 A CN93100940 A CN 93100940A CN 93100940 A CN93100940 A CN 93100940A CN 1079954 A CN1079954 A CN 1079954A
- Authority
- CN
- China
- Prior art keywords
- nabumetone
- spray
- frozen
- tablet
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007921 spray Substances 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- OLLZVOGJEBTAQV-UHFFFAOYSA-N butan-2-one;naphthalene Chemical compound CCC(C)=O.C1=CC=CC2=CC=CC=C21 OLLZVOGJEBTAQV-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 claims abstract description 7
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 59
- 229960004270 nabumetone Drugs 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 230000008014 freezing Effects 0.000 claims description 7
- 238000007710 freezing Methods 0.000 claims description 7
- 206010058019 Cancer Pain Diseases 0.000 claims description 6
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 208000010040 Sprains and Strains Diseases 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims 1
- 239000000047 product Substances 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coating By Spraying Or Casting (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Freezing, Cooling And Drying Of Foods (AREA)
- Sampling And Sample Adjustment (AREA)
- Road Signs Or Road Markings (AREA)
- Catching Or Destruction (AREA)
Abstract
具有比先前可能的体积小的、喷雾冷冻的和配制
成单位剂量形式的萘丁酮。
Description
本发明涉及喷雾冷冻的萘丁酮（nabumetone）和其生产方法。
GB 1，474，377描述了一种通常被称为萘丁酮的非甾族抗炎药4-（6-甲氧基-2-萘基）-丁-2-酮。该专利还描述了萘丁酮的生产方法。
萘丁酮最通常是作为500 mg或1000 mg吞咽片开处方。合成的含有萘丁酮和常规赋形剂的片剂体积相当大，对一些病人可能引起吞咽困难。
常规分离和碾磨过的萘丁酮的松装密度范围为0.35-0.39g/cm3，摇实密度范围为0.44-0.48g/cm3，当与常规的赋形剂混合后产生的片剂体积对于500 mg萘丁酮片为0.485 cm3，对于1000 mg萘丁酮片为0.970 cm3。
常规分离和碾磨过的萘丁酮通过与常规填料、表面活性剂和崩解剂混合而配制成常规的吞咽片。现已发现可与赋形剂，尤其是填料相混合的药物最大量是82%。进一步增大药物的百分比（即降低赋形剂，尤其是填料的百分比）引起片剂在生产、储存和转运过程中易于碎裂，这是一个很明显的缺点。
喷雾冷冻是一种已存在大约30多年的先有技术，已被用于生产食品如咖啡以及药品。
通常选择喷雾冷冻，是因为该方法产生均一的产品质量如粒度、含湿量和堆密度。
在药品生产中使用喷雾冷冻法，是因为该方法可以提供具有改进的流动特性的产品。
现已发现，喷雾冷冻的萘丁酮具有优良的配制特性，生产便宜，出人意料地可以用比先前需要的量少的赋形剂配制成可行的片剂。此外，喷雾冷冻过的萘丁酮具有意想不到的优点，它比常规分离和碾磨过的萘丁酮更密实，因此，可被配制成较小的易吞咽的片剂。
因此，本发明提供了喷雾冷冻的萘丁酮。
本发明进一步提供了松装密度范围为0.40-0.65g/cm3的喷雾冷冻的萘丁酮。
具体地讲，喷雾冷冻的萘丁酮的松装密度范围适宜地为0.45-0.60g/cm3，或更优选地是0.5-0.55g/cm3，最优选地约为0.5g/cm3。
本发明也提供了摇实密度范围为0.50-0.65g/cm3的喷雾冷冻的萘丁酮。
具体地讲，喷雾冷冻的萘丁酮的摇实密度适宜为0.54-0.62g/cm3，或更优选地为0.58-0.62g/cm3，最优选地约为0.60g/cm3。
本发明也提供了含有与可药用的载体混合的喷雾冷冻的萘丁酮的药物组合物。
应该理解，下文所用的赋形剂一词是指可药用载体。
本发明的另一方面提供了单位剂量形式的喷雾冷冻的萘丁酮。合适的单位剂量形式包括用制剂学领域中已知的常规技术形成的含萘丁酮的片剂、香囊、悬浮剂和栓剂。
本发明还提供了含500 mg与常规赋形剂混合的喷雾冷冻的萘丁酮的吞咽片，该片剂的体积为0.429 cm3。因此本发明提供了含500 mg喷雾冷冻的萘丁酮的吞咽片，该片的体积小于0.480cm3，优选小于0.450 cm3，最优选地小于0.430 cm3。
本发明还提供了含1000mg与常规赋形剂混合的喷雾冷冻的萘丁酮的吞咽片，该片剂的体积为0.858cm3。因此本发明提供了含1000mg喷雾冷冻的萘丁酮的吞咽片，该片的体积小于0.960 cm3，优选小于0.930cm3，最优选地小于0.860 cm3。
本发明还提供了不用或基本上不用常规填充剂作赋形剂制备的喷雾冷冻的萘丁酮的单位剂量制剂。
应该理解，填充剂是制剂学领域中通常承认的那些填充剂，例如，微晶纤维素、羟丙甲基纤维素、乳糖和淀粉。
本发明还提供了常规吞咽片，该片剂中喷雾冷冻的萘丁酮对赋形剂的百分比（w/w）大于82%，适宜是大于85%，更适宜的是大于88%，最好大于90%。
本发明的另一方面提供了制备喷雾冷冻的萘丁酮的方法，该方法包括，熔化固体萘丁酮，将之喷雾到喷雾冷冻器的冷冻室中，收集形成的产品。
优选地是将萘丁酮加热至高过其熔点（80℃）20℃使之熔化。
熔化后的萘丁酮以16-17kg/hr的速度送入冷冻室比较适宜。
冷冻室冷却至1-4℃比较适宜。
萘丁酮适宜地是通过2个流体喷嘴送入冷冻室，用热的压缩空气喷成雾状。形成的产品适宜地是收集在旋风收集器中。
上面所用的喷雾冷冻器适宜地是常规的市售的喷雾冷冻器。
用于喷雾冷冻的萘丁酮适宜地是按照在EP-A-003074（Beecham Group plc）或EP-A-0288144（Beecham Group plc）中概述的方法制备，但应该理解，用任何合适的手段制备的萘丁酮均可用于喷雾冷冻。
先前已有描述，萘丁酮可用于治疗炎症，特别是由风湿性关节炎或骨关节炎引起的那些炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征。因此，本发明提供了一种治疗炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的方法，该方法包括使需要该治疗的患者服用有效量的喷雾冷冻的萘丁酮。
本发明还提供了喷雾冷冻的萘丁酮在生产用于治疗炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的药物中的应用。
本发明还提供了用于治疗炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的药物组合物，其中包含与可药用载体混合的喷雾冷冻的萘丁酮。
下列实施例描述喷雾冷冻的萘丁酮的制备和分别含500mg和1000mg萘丁酮的吞咽片的形成。
实施例1
喷雾冷冻的萘丁酮的制备
将按EP-A-0003074中所述方法制备的萘丁酮熔化（80℃）并保持在大约100℃。然后用蠕动泵以16-17kg/hr的进料速度经2个流体（空气喷雾）喷嘴将熔体送入常规喷雾冷冻器的冷冻室中，在此用热的压缩空气在80 psi（要求国际单位）进行雾化。
然后当喷雾过的萘丁酮喷雾到保持在1-4℃的冷冻室中时将之冷却，用旋风收集器收集结晶产品。
上面所用的喷雾冷冻器是Drytech Ltd，46 Morley Road，Tonbridge，Kent，UK的市售产品。
实施例2（500 mg喷雾冷冻的萘丁酮吞咽片）
将下列诸组分按常规方法混合，并压缩成吞咽片。
500 mg 喷雾冷冻的萘丁酮
25mg ＊Explotab
2 mg 月桂基硫酸钠
527mg
实施例3（1000 mg喷雾冷冻的萘丁酮吞咽片）
将下列诸成分按常规方法混合，并压缩成吞咽片。
1000mg 喷雾干燥的萘丁酮
50mg ＊Explotab
4 mg 月桂基硫酸钠
1027mg
＊ 淀粉乙醇酸钠的商标。
Claims (12)
1、制备喷雾冷冻的萘丁酮的方法，其中包括熔化固体萘丁酮，把它喷雾到喷雾冷冻器的冷冻室中，收集形成的产品。
2、根据权利要求1的方法，其中喷雾冷冻的萘丁酮的松装密度范围为0.40-0.65g/cm3。
3、根据权利要求1的方法，其中喷雾冷冻的萘丁酮的摇实密度范围为0.50-0.65g/cm3。
4、制备药物组合物的方法，其中包括将按权利要求1的方法制备的喷雾冷冻的萘丁酮与可药用的载体混合。
5、根据权利要求4的方法，其中含有按照权利要求1制备的喷雾冷冻的萘丁酮的药物组合物为单位剂量形式。
6、根据权利要求5的方法，其中单位剂量形式是含500 mg与赋形剂混合的、按权利要求1的方法制备的喷雾冷冻的萘丁酮的吞咽片，该片的体积小于0.480 cm3。
7、根据权利要求5的方法，其中单位剂量形式是含1000mg与赋形剂混合的、按权利要求1的方法制备的喷雾冷冻的萘丁酮的吞咽片，该片的体积小于0.960 cm3。
8、根据权利要求5-7中任一项的方法，其中单位剂量形式没有或基本上没有填充剂作赋形剂。
9、根据权利要求6-8中任一项的方法，其中吞咽片中按照权利要求1制备的喷雾冷冻的萘丁酮对赋形剂的百分比（w/w）大于82%。
10、根据权利要求7的方法，其中吞咽片中喷雾冷冻的萘丁酮对赋形剂的百分比大于90%。
11、治疗炎症、扭伤、过劳、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的方法，其中包括使需要此种治疗的患者服用有效量的权利要求1-10中任一项的喷雾冷冻的萘丁酮。
12、权利要求1-10中任一项的喷雾冷冻的萘丁酮在生产用于治疗炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的药物中的应用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929201857A GB9201857D0 (en) | 1992-01-29 | 1992-01-29 | Novel compound |
| GB9201857.1 | 1992-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1079954A true CN1079954A (zh) | 1993-12-29 |
Family
ID=10709436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93100940A Pending CN1079954A (zh) | 1992-01-29 | 1993-01-28 | 喷雾冷冻的萘丁酮和其生产方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5539000A (zh) |
| EP (1) | EP0624087B1 (zh) |
| JP (1) | JPH07503245A (zh) |
| KR (1) | KR950700056A (zh) |
| CN (1) | CN1079954A (zh) |
| AT (1) | ATE150298T1 (zh) |
| AU (1) | AU3362693A (zh) |
| BG (1) | BG98933A (zh) |
| BR (1) | BR9305674A (zh) |
| CA (1) | CA2129027A1 (zh) |
| CZ (1) | CZ182894A3 (zh) |
| DE (1) | DE69309037T2 (zh) |
| DK (1) | DK0624087T3 (zh) |
| ES (1) | ES2099419T3 (zh) |
| FI (1) | FI943550A7 (zh) |
| GB (1) | GB9201857D0 (zh) |
| GR (1) | GR3023142T3 (zh) |
| HU (1) | HUT67462A (zh) |
| IL (1) | IL104526A0 (zh) |
| MX (1) | MX9300430A (zh) |
| NO (1) | NO942813D0 (zh) |
| SK (1) | SK91694A3 (zh) |
| WO (1) | WO1993014747A1 (zh) |
| ZA (1) | ZA93577B (zh) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| GB9920148D0 (en) * | 1999-08-25 | 1999-10-27 | Smithkline Beecham Plc | Novel composition |
| TWI262791B (en) | 1999-10-27 | 2006-10-01 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
| US6552078B2 (en) | 1999-10-27 | 2003-04-22 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
| US6436990B1 (en) | 1999-10-27 | 2002-08-20 | Nobex Corporation | 6-methoxy-2-naphthylacetic acid prodrugs |
| US20020132010A1 (en) * | 2000-12-22 | 2002-09-19 | Yihong Qui | Divalproex sodium dosage forms and a process for their production |
| US20060083791A1 (en) | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
| US20040161474A1 (en) * | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
| US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
| KR20080064209A (ko) * | 2003-12-04 | 2008-07-08 | 화이자 프로덕츠 인코포레이티드 | 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법 |
| WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| EP1689368B1 (en) * | 2003-12-04 | 2016-09-28 | Bend Research, Inc | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions |
| PL1691787T3 (pl) * | 2003-12-04 | 2008-11-28 | Pfizer Prod Inc | Sposób wytwarzania farmaceutycznych systemów wielocząstkowych |
| CA2547597A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
| WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
| RU2006119453A (ru) * | 2003-12-04 | 2007-12-20 | Пфайзер Продактс Инк. (Us) | Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц |
| US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| US20060134225A1 (en) * | 2004-10-15 | 2006-06-22 | Moerck Rudi E | Phosphate binder with reduced pill burden |
| WO2007022445A2 (en) * | 2005-08-17 | 2007-02-22 | Altairnano, Inc. | Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods |
| US7541384B2 (en) * | 2007-06-08 | 2009-06-02 | Axcan Pharma Inc. | Mesalamine suppository |
| US8436051B2 (en) | 2007-06-08 | 2013-05-07 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
| US8217083B2 (en) * | 2007-06-08 | 2012-07-10 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| CA2798081C (en) | 2010-05-12 | 2024-02-13 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| WO2016205423A2 (en) | 2015-06-15 | 2016-12-22 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| CA3078723A1 (en) | 2016-11-28 | 2018-05-31 | Nachiappan Chidambaram | Oral testosterone undecanoate therapy |
| US12150945B2 (en) | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4420639C1 (en) * | 1973-09-11 | 2001-08-21 | Beecham Group Ltd | Aromatic compounds |
| GB1474377A (en) | 1973-09-11 | 1977-05-25 | Beecham Group Ltd | Naphthalene derivatives |
| US4086346A (en) | 1974-04-06 | 1978-04-25 | Bayer Aktiengesellschaft | Preparation of melt-sprayed spherical phenacetin granules |
| DE3833446A1 (de) | 1988-10-01 | 1990-04-05 | Hoechst Ag | Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten |
-
1992
- 1992-01-29 GB GB929201857A patent/GB9201857D0/en active Pending
-
1993
- 1993-01-22 EP EP93902444A patent/EP0624087B1/en not_active Expired - Lifetime
- 1993-01-22 JP JP5513026A patent/JPH07503245A/ja active Pending
- 1993-01-22 BR BR9305674-5A patent/BR9305674A/pt unknown
- 1993-01-22 WO PCT/GB1993/000145 patent/WO1993014747A1/en not_active Ceased
- 1993-01-22 ES ES93902444T patent/ES2099419T3/es not_active Expired - Lifetime
- 1993-01-22 CZ CZ941828A patent/CZ182894A3/cs unknown
- 1993-01-22 AT AT93902444T patent/ATE150298T1/de active
- 1993-01-22 AU AU33626/93A patent/AU3362693A/en not_active Abandoned
- 1993-01-22 HU HU9402221A patent/HUT67462A/hu unknown
- 1993-01-22 KR KR1019940702615A patent/KR950700056A/ko not_active Withdrawn
- 1993-01-22 DE DE69309037T patent/DE69309037T2/de not_active Expired - Fee Related
- 1993-01-22 SK SK916-94A patent/SK91694A3/sk unknown
- 1993-01-22 DK DK93902444.4T patent/DK0624087T3/da active
- 1993-01-22 FI FI943550A patent/FI943550A7/fi not_active Application Discontinuation
- 1993-01-22 CA CA002129027A patent/CA2129027A1/en not_active Abandoned
- 1993-01-22 US US08/030,331 patent/US5539000A/en not_active Expired - Fee Related
- 1993-01-27 ZA ZA93577A patent/ZA93577B/xx unknown
- 1993-01-27 IL IL104526A patent/IL104526A0/xx unknown
- 1993-01-27 MX MX9300430A patent/MX9300430A/es unknown
- 1993-01-28 CN CN93100940A patent/CN1079954A/zh active Pending
-
1994
- 1994-07-28 BG BG98933A patent/BG98933A/xx unknown
- 1994-07-28 NO NO942813A patent/NO942813D0/no unknown
-
1997
- 1997-04-15 GR GR970400804T patent/GR3023142T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2099419T3 (es) | 1997-05-16 |
| WO1993014747A1 (en) | 1993-08-05 |
| DE69309037T2 (de) | 1997-07-24 |
| EP0624087A1 (en) | 1994-11-17 |
| DE69309037D1 (de) | 1997-04-24 |
| ZA93577B (en) | 1994-01-13 |
| MX9300430A (es) | 1994-08-31 |
| GB9201857D0 (en) | 1992-03-18 |
| NO942813L (no) | 1994-07-28 |
| JPH07503245A (ja) | 1995-04-06 |
| SK91694A3 (en) | 1995-03-08 |
| KR950700056A (ko) | 1995-01-16 |
| CZ182894A3 (en) | 1995-02-15 |
| AU3362693A (en) | 1993-09-01 |
| IL104526A0 (en) | 1993-05-13 |
| CA2129027A1 (en) | 1993-08-05 |
| GR3023142T3 (en) | 1997-07-30 |
| EP0624087B1 (en) | 1997-03-19 |
| FI943550A0 (fi) | 1994-07-28 |
| HU9402221D0 (en) | 1994-09-28 |
| HUT67462A (en) | 1995-04-28 |
| ATE150298T1 (de) | 1997-04-15 |
| DK0624087T3 (da) | 1997-09-01 |
| BR9305674A (pt) | 2005-01-11 |
| US5539000A (en) | 1996-07-23 |
| NO942813D0 (no) | 1994-07-28 |
| BG98933A (en) | 1995-07-28 |
| FI943550L (fi) | 1994-07-28 |
| FI943550A7 (fi) | 1994-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1079954A (zh) | 喷雾冷冻的萘丁酮和其生产方法 | |
| JP4846158B2 (ja) | Ｎ−［４−［２−（２−アミノ−４，７−ジヒドロ−４−オキソ−３Ｈ−ピロロ［２，３−ｄ］ピリミジン−５−イル）エチル］ベンゾイル］−Ｌ−グルタミン酸の新規結晶形およびその製造方法 | |
| CN1040746C (zh) | 维生素d类似物的新晶形 | |
| CN1270516A (zh) | 含氯甲双磷酸盐活性成分和硅化微晶纤维素赋形剂的药物制剂 | |
| JP2010500411A5 (zh) | ||
| CN1190891A (zh) | 二－β－D－吡喃葡萄胺化合物控制发炎反应的用途及其合成方法 | |
| CN1382682A (zh) | 2－(α－羟基戊基)苯甲酸盐及其制法和用途 | |
| CN1575163A (zh) | 孟鲁司特颗粒制剂 | |
| MXPA01011071A (es) | Composicion farmaceutica en forma unitaria que contiene acido acetilsalicilico e hidrogenosulfato de clopidogrel. | |
| CN1612859A (zh) | 结晶[R－(R*，R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]-1H-吡咯-庚酸钙盐(2∶1) | |
| CN1223589C (zh) | 穿心莲内酯琥珀酸半酯钠钾盐及其制剂 | |
| US5047525A (en) | 9-haloprostaglandin clathrates and their use as medicines | |
| CN1244120A (zh) | 注入堆积密度为0.28～0.38g/ml的含有特布他林硫酸盐的吸入用新配方法、该配方的制备方法及其用途 | |
| US20080292730A1 (en) | Nutritional supplement for osteoarthritis | |
| WO1991004737A1 (en) | Osteogenesis promoter | |
| JPH10505822A (ja) | 共−乾燥されたスクラルファートゲル及びポリアルコールを含む製薬学的組成物 | |
| WO2014125085A1 (en) | Oral pharmaceutical formulations comprising nimesulide and thiocolchicoside | |
| JP2004059585A (ja) | 安定な非晶質カルシウム・シュードモネイト及びその調製方法 | |
| EP0006223A1 (en) | Crystalline sodium and potassium indomethacin and their trihydrates, process for preparing and pharmaceutical compositions containing the same | |
| CN1473568A (zh) | 用于治疗感冒的含有布洛芬的药物组合物 | |
| RU2821102C2 (ru) | Твердые формы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты | |
| CN1088600C (zh) | 布洛芬－β－环糊精配合物的用途 | |
| CN100448452C (zh) | 治疗剂 | |
| AU2009338480A1 (en) | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative | |
| WO2025212048A1 (en) | Pharmaceutical compositions comprising ibuprofen and paracetamol and relevant excipients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |